This review highlights the critical role of the Gαq/PLC βI/PKC signal transduction pathway in mediating cardiac hypertrophy and contractile dysfunction, providing insights into the molecular pathogenesis of heart failure.
Answers are grounded in this paper and cite their sources.
Supports Gαq as research target in hypertrophy; leaves open clinical translation amid redundant pathways.
Time for primary review 34 days. Currently the precise biochemical pathogenesis of cardiac hypertrophy remains unclear. A great deal of investigation has been directed toward the examination of various signal transduction pathways that are thought to be involved in stimulating this process. In particular, the signaling pathways that use heterotrimeric G protein-coupled receptors have been the focus for many investigations. This review will focus on the function of the Gαq family of proteins and its downstream effectors during cardiac hypertrophy. Hypertrophy is the final common pathway for a variety of insults to the normal cardiovascular system. Many mechanical and hormonal stimuli such as hypertension, valve disorders, and ischemic events, can produce a hypertrophic response. These pathologic stimuli cause an increase in the workload placed upon the heart resulting in hypertrophy and remodeling that has been observed at the myocyte [1] and the gross anatomical level. Current thought suggests that the hypertrophic response is a compensatory mechanism that allows normal cardiac function against a gradient of increasing workload. If the pathologic stimulus is sufficiently intense or prolonged, a period of failure characterized by impaired function, dilation of the left ventricle, and pulmonary congestion ensues. Recently, experiments using cardiac specific transgenesis to investigate G protein-mediated mechanisms of cardiac hypertrophy have yielded novel information that may give us cause to re-evaluate our traditional stratification of hypertrophic states [2]. It is important to evaluate these results along with other conventional and transgenic models so that we can develop a more comprehensive understanding of this complex disease. Heterotrimeric G protein-coupled receptors serve to convey an extracellular biochemical signal to intracellular effectors. These receptors are heptahelical structures with extracellular, transmembrane, and intracellular domains coupled to specific G proteins which are comprised of three (α, β, γ) subunits. When the G protein complex is in the inactive state, guanosine diphosphate (GDP) is bound to the α subunit while the βγ dimer acts to stabilize this conformation (Fig. 1). After ligand binding, a conformational shift in the G protein complex occurs resulting in a decreased affinity of the α subunit for GDP. The active state for Gα begins when GDP is exchanged for GTP, followed by disassociation of the α subunit from the rest of the G protein complex. Gα proteins serve to activate a number of effectors such as adenylate cyclase, phospholipase C β (PLC β), and ion channels [3]. Gβγ can also act as a signal transducer as demonstrated by its ability to stimulate PLC activity in vitro [4]. Deactivation of Gα occurs when GTP is hydrolyzed to GDP, a process mediated by the intrinsic GTPase activity of Gα, as well as GTPase activating proteins (GAPs). Gα with bound GDP will re-associate with the βγ dimer, forming a heterotrimeric complex that is poised for re-activation by the next extracellular signal. G coupled receptor activation of protein kinase C (PKC) in cardiac muscle. When extracellular agonists such as endothelin I, angiotensin II, or phenylephrine bind to the G protein-coupled receptor complex a conformational shift in the G protein complex results in the displacement of GDP and binding of GTP to the Gαq subunit. Upon GTP binding, Gαq is released from the complex and activates phospholipase C βI (PLC βI). A class of molecules known as regulators of G protein signaling (RGS) can activate the intrinsic GTPase activity of Gαq to hydrolyze GTP to GDP, resulting in Gαq inactivation and re-association with the βγ dimer. PLC βI catalyzes the hydrolysis of phosphotidylinositol bisphosphate (PIP2) into diacylglycerol (DAG) and inositol triphosphate (IP3). IP3 binds to the IP3 receptor on the sarcoplasmic reticulum (SR) and causes release of calcium into the cytosol. The IP3 receptor itself comprises about 5% of the calcium channels on the SR whereas the ryanodine receptor (RYR) comprises about 95% of these channels in heart muscle. Calcium released into the cytosol by the IP3 receptor binds to the calcium sensitive isoforms of PKC (PKC α, βI, βII, γ) resulting in translocation of PKC to the cell membrane. Once PKC is translocated to the cell membrane it is activated by DAG and begins to phosphorylate various cell proteins hypothesized to play a critical role in cardiac hypertrophy such as transcription factors, Na+/H+ exchanger, myofilament proteins, and voltage-dependent calcium channels. The activation potential of Gα proteins can be influenced by several factors including half-life (which is dependent on its intrinsic GTPase activity), post-translational modification, extrinsic modification of GTPase activity, and Gαq expression levels present in the cell [3]. GTPase activating proteins (GAPs) also serve to increase the intrinsic GTPase activity of Gα. Recently, a new class of GAPs has been characterized that may play a critical role in regulating G protein activity. These are named regulators of G protein signaling (RGS). To date eight RGS subtypes have been identified that stimulate Gα-mediated GTP hydrolysis, all with differential specificity directed toward the various Gα proteins [5]. There are currently four classes of Gα proteins identified; αs, αi, α12, and αq[6]. The Gαs family consists of αs and αolf, that stimulate adenylate cyclase. The Gαi family includes αi-1, αi-2, and αi-3 that are inhibitors of adenylate cyclase, αz and αo that regulate potassium and calcium channels, and αt-1, αt-2, and αgust that activate cyclic GMP phosphodiesterase. Members of the Gα12 family of α12 and α13 are postulated to regulate the Na+/H+ exchanger. The Gαq family of proteins consisting of Gαq, Gα11, Gα14, Gα15, and Gα16 are activators of PLC β. Previous experiments using cultured neonatal cardiomyocytes have demonstrated that both G protein agonists such as angiotensin II, as well as mechanical stretch, can stimulate a hypertrophic response [7–9]. These early studies implicated a role for the involvement of this G protein signaling pathway in the development of cardiac hypertrophy. The recent revolution in cardiac specific mouse transgenesis has facilitated more detailed in vivo experiments aimed at delineating the role of G protein mediated signaling in cardiac hypertrophy. Over expression of Gαq in the mouse has been used to assess its role in cardiac hypertrophy. D’Angelo et al. [10] produced three separate lines of transgenic mice with various levels of cardiac specific overexpression of Gαq. This study found cardiac hypertrophy at the whole heart level, recapitulation of the fetal gene program, and increased mortality in a gene dose dependent manner. The downstream signaling protein PKC ε was also activated in this model. Furthermore, echocardiographic and invasive high fidelity micromanometer hemodynamic studies revealed significant contractile depression associated with the cardiac hypertrophy, and this contractile dysfunction was observed at the myocyte level as well. This model, however, presented some unique aspects in its hypertrophic phenotype. In spite of whole heart hypertrophy, there was no appreciable left ventricular (LV) hypertrophy present during Gαq overexpression. This presents an interesting scenario where LV myocyte dysfunction and contractile depression exists without concomitant LV hypertrophy. This unique aspect was explored further when experimental banding of the Gαq overexpression mouse was performed. Superimposing hemodynamic stress (via constriction of the aorta) upon a mouse that had basal cardiac dysfunction lead to the development of classic decompensated cardiac hypertrophy characterized by LV hypertrophy, pulmonary congestion and continued impaired contractile parameters [2]. Furthermore, it was also observed that the greater the level of Gαq expression, the quicker the onset of decompensated heart failure. Thus, it appears that even though Gαq overexpression produces a unique compromised type of cardiomyopathy that is neither compensated or decompensated, it can progress to classic decompensation with the superimposition of hemodynamic stress. Inhibiting Gαq signaling may be an approach to prevent cardiac hypertrophy from occurring through pressure overload stimuli. This has been investigated in mice using cardiac-specific overexpression of a peptide fragment derived from the carboxy terminus of Gαq that can effectively block Gαq receptor coupling [11]. Pressure overload, induced by constriction of the aorta, results in substantially less cardiac hypertrophy in transgenic mice overexpressing the Gαq inhibitor peptide than in wild type controls. Gαq inhibitor mice developed a moderate degree of hypertrophy that fell between the level of hypertrophy observed in non surgically treated Gαq controls and surgically banded wild types. Incomplete attenuation of pressure overload induced hypertrophy in Gαq inhibitor mice suggests that other signaling pathways, perhaps tyrosine kinase mediated, may also be playing a role in the development of cardiac hypertrophy. These transgenic mice also had a blunted response to direct ventricular injection of the G protein agonists angiotensin II, endothelin I, and phenylephrine. In contrast, studies using mice with targeted ablation of the angiotensin II type 1A (AT1) receptor revealed that pressure overload continued to induce cardiac hypertrophy [12,13]. This result, however, suggests the presence of unknown, yet redundant pathways that may mediate a hypertrophic response. In broadly evaluating these studies one can conclude that Gαq receptor coupling via several extracellular signals directly stimulates the hypertrophic response, but there are clearly other cell signaling systems unrelated to Gαq that play a role in the development of hypertrophy. Furthermore, it can be inferred that Gαq signaling, independent of hemodynamic load leads to contractile dysfunction at the myocyte level. Four types of PLC β exist; PLC β1, PLC β2, PLC β3, and PLC β4. Sensitivity for activation by Gαq is greatest with PLC β1 and PLC β3 [3]. In the heart, PLC β1 is the major isoform expressed [4] while PLC β3 is expressed in all tissues [3]. PLC β2 has been found in smooth muscle, brain tissue, and liver [14]. PLC β4 appears to exist only in the retina [15] and specific areas of the brain [16]. Once active, these isoforms of PLC β cleave membrane bound phosphotidylinositol bisphosphate (PIP2) into diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). These products serve to activate various downstream protein kinase C (PKC) isoforms as described in more detail in the following section. It is interesting to note that Gαq activity can be influenced by the concentration of PLC β1 as well. In vitro systems using Gαq in reconstituted lipid vesicles have demonstrated that the rate of GTP hydrolysis increases up to 50-fold following addition of PLC β1 [17]. In addition, Gαq-mediated GTP hydrolysis was observed to be at one half of maximal velocity when PLC βI levels were 2-fold greater than Gαq, and at maximal velocity when PLC βI levels were 20–30-fold greater than Gαq[17]. Thus, a negative feedback loop may exist such that high concentrations of PLC βI can reduce Gαq activity by increasing the rate of GTP hydrolysis. The products of PIP2 hydrolysis, DAG and IP3, are potent activators of protein kinase C (PKC). PKC, an important enzyme family of serine–threonine kinases, plays a role in the cellular response to hormones, growth factors and neurotransmitters such as endothelin I, angiotensin II, and α1-adrenoreceptors [18,19], all of which are signaled by Gαq coupled receptors. Mammalian PKCs are comprised of 11 isoforms: conventional isoforms responsive to calcium (α, βI, βII, γ); novel isoforms that lack the calcium binding site (δ, ε, η, θ); and atypical isoforms that do not respond to phorbol esters (ζ, λ, μ) [20]. PKC isoforms consist of a single polypeptide chain that contains an amino-terminal regulatory region and a carboxy-terminal kinase domain [21]. All PKC isoforms contain a highly conserved carboxy-terminal kinase domain (C3 and C4). PKC isoforms differ in their amino-terminal regulatory regions. The regulatory region of PKCs contains an autoinhibitory domain, the C1 domain, and the C2 domain. The C1 domain binds DAG and phorbol esters, and the C2 domain binds acidic phospholipids and Ca2+. Activation of PKC requires the removal of the autoinhibitory domain from the active site. IP3 induces calcium release from sarcoplasmic reticulum stores, resulting in the translocation of the Ca2+ sensitive PKC. Following translocation to the membrane, DAG (mimicked by phorbol esters) activates conventional and novel PKC isoforms. Once active, PKC modulates activity of transcription factors (c-jun and fos) and gene expression [22,23], voltage-dependent calcium channels [24], Na+/H+ exchanger [25], sarcoplasmic reticular proteins [26], and myofilament proteins troponin I and troponin T [27,28]. It has been demonstrated that the PKC activation process involves binding with a group of proteins termed RACKs (receptors of activated C-kinase). These proteins are specific for various PKC isoforms and serve to localize PKC to specific compartments in the cell. Among these, PKC α, βII, and ζ are translocated from the cytosol to perinuclear membrane while PKC ε translocates from the nucleus to myofibrils [29]. Through these RACK–PKC interactions, activated PKCs are trafficked to modulate the targets listed above via phosphorylation of serine threonine residues. Extracellular signals that elicit a response via Gαq have been observed to stimulate PKC isoforms in neonatal cardiomyocytes. PKC is hypothesized to modulate cardiac hypertrophy by phosphorylation of transcription factors controlling expression of hypertrophic genes. Among these transcription factors found to be modulated by PKC in agonist stimulated cardiomyocytes are c-jun and fos[22]. Signal transduction cascades such as p42 and p44 MAPK isoforms (mitogen-activated protein kinase) that lead to c-jun and fos activation have also been found to be activated by PKC in agonist-stimulated cardiomyocytes [30]. Similar observations have been published using animal models of cardiac hypertrophy as well. Pressure overload in rats induces the translocation of PKC ε, βI, and βII and increases PKC-dependent phosphorylation activity [31]. Acute pathological levels of mechanical stretch of the left ventricle in the isolated adult guinea pig heart results in rapid translocation of PKC ε, but not other isoforms [32]. Results from our laboratory have also indicated that in the guinea pig model with constriction of the descending thoracic aorta for a period of 8 weeks, PKC α and ε is upregulated during decompensated cardiac hypertrophy [33]. Using well-established methods of cardiac specific transgenesis, the effects of overexpressing the βII isoform of PKC have been examined in transgenic mice. Overexpression of PKC βII produces a hypertrophic phenotype, upregulation of the fetal gene program, and myocyte dysfunction, with no change in systemic blood pressure [34]. Taken together, the observations in cell culture and animal models implicate PKC isoforms as an important signal transduction pathway in the development of cardiac hypertrophy. This notion is further supported by the fact that when PKC βII overexpression mice are treated with an oral PKC βII inhibitor beginning at 3 weeks of age, the hypertrophic phenotype is largely prevented from occurring. In addition, we have recently demonstrated that inhibition of PKC translocation by an angiotensin-converting enzyme inhibition is accompanied by improved cardiomyocyte and isolated isovolumic left ventricular function during pressure overload hypertrophy and failure [33]. Though evidence is mounting for hypertrophic signaling via PKC, the fundamental question of relevance to the human condition of hypertrophy has not been addressed until recently. Examination of explanted human hearts has revealed upregulation of mRNA expression for PKC βI and βII isoforms, significant translocation of PKC α, βI, βII, and an increase in PKC activity [35]. Even though there are species specific differences present in the differential PKC isoform response during cardiac hypertrophy, the activation of PKC in general is a common pathway. Taken together these recent data from conventional animal models, genetically engineered mice and human myocardium implicate activation of the Gαq, phospholipase C β, protein kinase C pathway as a major determinant of cardiac hypertrophy and heart failure. Inhibitors of this signal transduction system at multiple levels, while using established methods to reduce afterload, may provide a promising therapeutic approach to this clinically important syndrome.
No takes yet. Share an insight, caveat, or question.
Thunder Jalili (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: